Table 1

Baseline characteristics of patients with pSS and healthy controls

TotalPfizer-Biontech
(BNT162b2)
Astrazeneca
(ChAdOx1 nCoV-19)
Moderna
(mRNA-1273)
Janssen
(Ad.26.COV2.S)
pSS (n=67)HC (n=33)pSS (n=47)HC (n=14)pSS (n=13)HC (n=5)pSS (n=6)HC (n=8)pSS (n=1)HC (n=6)
Gender (female)58 (87)33 (100)40 (85)14 (100)12 (92)5 (100)5 (83)8 (100)1 (100)6 (100)
Age59 (51–67)*41 (33–62)*58 (49–69)57 (37–68)63 (61–66)61 (48–64)45 (35–56)28 (26–39)5340 (34–46)
Hydroxychloroquine use15 (22)n/a10 (21)n/a5 (38)n/a0n/a0n/a
ESSDAI (total)3 (1–4)†n/a3 (1–5)†n/a3 (2–5)n/a2 (0–4)†n/a2n/a
ESSDAI <546 (78)30 (75)10 (77)5 (100)1 (100)
ESSDAI 5–1413 (22)10 (25)3 (23)0
ESSDAI ≥140000
Physician GDA2 (1–2)‡n/a2 (1–2)‡n/a2 (1–3)†n/a1 (1–2)§n/a1n/a
ESSPRI (total)6 (5–7)n/a6 (5–7)n/a6 (5–8)n/a7 (6–8)n/a3n/a
Patient GDA6 (5–7)n/a6 (5–7)n/a7 (6–8)n/a7 (6–8)n/a4n/a
IgG (g/L)13 (10–19)¶**10 (10–13)¶**13 (10–19)**10 (10–14)‡12 (9–16)‡9 (–)§11 (10–15)11 (10–14)†1112 (9–13)
Anti-SSA positive49 (73)n/a35 (74)n/a11 (85)n/a2 (33)n/a1n/a
RF positive34 (55)**n/a25 (58)**n/a7 (54)n/a1 (20)†n/a1n/a
  • Data presented as median (IQR) or n (%).

  • ESSDAI, physician GDA and RF collected ≤1 year before first vaccination date.

  • *Significant difference (p<0.005) between pSS and HC group.

  • †10%–20%.

  • ‡20%–30%.

  • §30%–40% missing data.

  • ¶Significant difference (p<0.05) between pSS and HC group.

  • **1%–10%.

  • ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; GDA, global disease activity; HC, healthy controls; n/a, not applicable; pSS, primary Sjögren’s syndrome; RF, rheumatoid factor.